Merck launches Vivera in Latin America
- Details
- Category: Merck
Merck, a leading science and technology company, today announced the launch of its new consumer brand Vivera® in Latin America. Vivera is being launched first in Chile in January 2016, to be followed by several major Latin American markets later in 2016.
Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in schizophrenia
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS receptors.
Sanofi Pasteur provides key support to the Human Vaccines Project
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of Sanofi, has signed an agreement with the Human Vaccines Project Inc. to partially fund the non-profit, public-private partnership convening leading academic researchers and industrial partners to solve the primary problems impeding vaccine/immunotherapy development by "decoding" the human immune system.
Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology
- Details
- Category: Novartis
Novartis has announced that it is adding to its diverse and deep immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology. The agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment.
Shire to combine with Baxalta, creating the global leader in rare diseases
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPG) and Baxalta Incorporated (NYSE: BXLT) announced that the boards of directors of both companies have reached an agreement under which Shire will combine with Baxalta.
Pfizer expands R&D equity investment strategy to access early-stage scientific innovations
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has announced an expansion of its Research & Development (R&D) investment strategy to include early-stage companies on the leading edge of scientific innovation, providing them with both equity and access to resources for research in promising areas aligned with Pfizer's core interests.
AstraZeneca and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise immuno-oncology mRNA therapeutics™
- Details
- Category: AstraZeneca
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics announced a new collaboration to discover, co-develop and co-commercialise messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers.
More Pharma News ...
- Merck Acquires IOmet Pharma and expands immuno-oncology development program
- Bayer halves the price of its contraceptive implant Jadelle® for women in developing countries
- Sanofi Genzyme announces recipients of Patient Advocacy Leadership (PAL) awards
- Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
- Merck KGaA, Darmstadt, Germany, Pfizer and Syndax announce collaboration to evaluate combination of Avelumab and Entinostat in ovarian cancer
- Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
- Bayer and CRISPR Therapeutics AG join forces to discover, develop and commercialize potential cures for serious genetic diseases